MedTrace Logo

Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model

NCT01479374 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 397

Last updated 2013-06-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AL-4943A ophthalmic solution

DRUG

AL-4943A vehicle

Inactive ingredients used as placebo

DRUG

Olopatadine hydrochloride ophthalmic solution, 0.2%

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Abhijit Narvekar, MS, MBBS · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-03-31
Completion
2012-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01479374 on ClinicalTrials.gov